GSE174036 tryptophan 4 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE174036_tryptophan_4_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE174036_tryptophan_4_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE174036_tryptophan_4_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE174036_tryptophan_4_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

SACS antisense RNA 1

Gene

RNA, 7SL, cytoplasmic 363, pseudogene

Gene

eukaryotic translation elongation factor 1 alpha 1 pseudogene 49

Gene

RNA, U1 small nuclear 83, pseudogene

Gene

SREK1IP1 pseudogene 2

Gene

MESD pseudogene 1

Gene

CAMTA1 antisense RNA 3

Gene

RNA, U6 small nuclear 432, pseudogene

Gene

RNA, 5S ribosomal pseudogene 310

Gene

cytochrome c oxidase subunit 6B1 pseudogene 6

  • Gene

    SACS antisense RNA 1


  • Gene

    RNA, 7SL, cytoplasmic 363, pseudogene


  • Gene

    eukaryotic translation elongation factor 1 alpha 1 pseudogene 49


  • Gene

    RNA, U1 small nuclear 83, pseudogene


  • Gene

    SREK1IP1 pseudogene 2


  • Gene

    MESD pseudogene 1


  • Gene

    CAMTA1 antisense RNA 3


  • Gene

    RNA, U6 small nuclear 432, pseudogene


  • Gene

    RNA, 5S ribosomal pseudogene 310


  • Gene

    cytochrome c oxidase subunit 6B1 pseudogene 6

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.